Presentations
SOL-116 Development Plan (2024-27)
Redeye: Ola Sandborgh, CEO, shares latest updates on the SOL-116 project.
June 11, 2025
“Excellent results that prepare us for phase II.”
Redeye: Interview with Ola Sandborgh, CEO, about the company’s recent year-end report and the positive clinical results with lead candidate SOL-116.
February 26, 2025
“Our project is all about a new, unique treatment for inflammatory diseases.”
Redeye: Ola Sandborgh, CEO, presents at Redeye Technology & Life Science Day 2024
December 3, 2024
“It’s a fantastic company and a really interesting project we are working on.”
Biostock: Ola Sandborgh, CEO, presents Lipum at BioStock Life Science Summit 2024.
November 24, 2024
“Our mission is to develop safer and more effective treatments for chronic inflammatory diseases with significant medical needs”
Redeye: Ola Sandborgh, CEO, is being interviewed at Redeye’s annual event on the theme of autoimmune and inflammatory diseases.
November 20, 2024